Hormone · Labels checked 2026-08-15
Vaginal estrogen, priced and read off the label
Everyone tells you local vaginal estrogen barely enters the bloodstream. Here is the number behind that sentence, printed on the Imvexxy (estradiol vaginal inserts) label and quoted almost nowhere: after 14 daily doses, mean serum estradiol was 3.6 pg/mL on the 4 mcg insert, 4.6 pg/mL on the 10 mcg insert, and 4.3 pg/mL on placebo. The placebo arm sat between the two active doses. It also carries the lowest per-month figure any platform on our roster publishes for any hormone product: Wisp prices its vaginal cream from $20/mo. Below: what it treats, what the labels claim, and what each of the 4 platforms we verify charges.
What is vaginal estrogen?
Vaginal estrogen is estrogen delivered directly into the vagina as a cream, an insert or a ring, at a dose measured in micrograms and intended to act on the local tissue rather than on the whole body. It works by restoring estrogen to the vaginal and urethral lining, which thins, loses elasticity and loses its normal acidity once ovarian estrogen falls, producing dryness, pain with sex, urinary urgency and repeat urinary tract infections. Vaginal estrogen and systemic hormone therapy are different prescriptions with different jobs: a patch or a pill is dosed to reach the bloodstream and treat hot flashes, and a vaginal product is dosed to stay largely where it is placed.
Local vaginal estrogen products are FDA-approved prescription medicines with published labels. Compounded vaginal hormone preparations sold by some telehealth platforms are mixed by a pharmacy, are not FDA-approved, and have no registration trial or label behind them. What bioidentical actually means.
What genitourinary syndrome of menopause is, and why it does not pass
Hot flashes fade. This does not. Genitourinary syndrome of menopause is the current name for the cluster that used to be called vulvovaginal atrophy: vaginal dryness, burning, pain with sex, and the urinary half that the old name left out, which is urgency, frequency and recurrent urinary tract infections. The 2014 terminology paper renamed it for that reason.
The difference that matters for a treatment decision: vasomotor symptoms are driven by the transition and generally settle over years, and this is driven by the ongoing absence of estrogen in tissue that depends on it. It tends to persist, it tends to progress slowly, and it returns when treatment stops. That is why local treatment here is normally long-term rather than a short course, and it is also why systemic HRT alone is often not enough: a systemic dose aimed at hot flashes can leave the local symptoms undertreated, which is the gap a woman on a patch who still has pain with sex is describing.
The 2014 systematic review of vaginal estrogen for this indication and the Menopause Society 2020 position statement are the two references a clinician will recognise if you bring them.
Local against systemic: what the labels actually claim
Low systemic absorption is the reason this route is treated as a different risk conversation from a patch or a pill. The labels report the numbers, so the claim is checkable rather than reassuring. Each card below also carries the label's own approved indication, which is narrower than the condition this route is usually discussed as treating: not one of them names a urinary indication.
Approved for. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
Dosing. One ring inserted into the upper third of the vaginal vault and worn continuously for three months, then replaced. The ring holds a 2 mg reservoir and releases about 7.5 mcg of estradiol per day over 90 days.
Systemic readout. Mean steady-state serum estradiol of 7.8, 7.0, 7.0 and 8.1 pg/mL at weeks 12, 24, 36 and 48 in 222 postmenopausal women who inserted up to four rings consecutively at three-month intervals. The label puts the mean systemically absorbed dose at about 8 percent of the amount released locally each day, 95 percent CI 2.8 to 12.8 percent.
Boxed warning section present: no
Approved for. Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Dosing. One insert placed about two inches into the vaginal canal daily for two weeks, then one insert twice weekly, every three to four days. Therapy generally starts at the 4 mcg strength.
Systemic readout. After 14 daily doses the mean estradiol Cavg over 24 hours, unadjusted for baseline, was 3.6 pg/mL on the 4 mcg insert, 4.6 pg/mL on the 10 mcg insert and 4.3 pg/mL on placebo. The figures come from a pharmacokinetic substudy of 54 women inside a 574-woman trial.
Boxed warning section present: yes
Approved for. Treatment of atrophic vaginitis due to menopause.
Dosing. One insert daily for two weeks, then one insert twice weekly, given intravaginally with the supplied applicator.
Systemic readout. In 29 patients on the 10 mcg insert, mean estradiol Cavg over 24 hours fell from 10.09 pg/mL on day 1 to 7.35 pg/mL on day 14 and 5.50 pg/mL on day 83.
Boxed warning section present: yes
Approved for. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
Dosing. 2 to 4 g on the marked applicator daily for one or two weeks, then gradually reduced to half that for a similar period. The label says a maintenance dose of 1 g one to three times a week may be used once the vaginal mucosa has been restored.
Systemic readout. This label reports no multiple-dose serum estradiol table of the kind the ring and insert labels carry, so a per-dose systemic figure cannot be quoted from it.
Boxed warning section present: yes
Read those two systemic readouts together. On the Imvexxy (estradiol vaginal inserts) label the placebo arm measured 4.3 pg/mL, higher than the 4 mcg insert's 3.6 and lower than the 10 mcg insert's 4.6. Those three means are printed unadjusted for baseline, so the label is reporting a treated woman and an untreated one landing in the same narrow band. On the Estring (estradiol vaginal system)label about 8 percent of what the ring releases each day is absorbed systemically. That is what “minimal systemic absorption” is standing on.
It supports a narrower claim than the one usually made from it. Low measured exposure is not the same finding as proven long-term safety, and every product above still carries the class contraindications, including known or suspected estrogen-dependent cancer and a history of breast cancer on some of them. In the Women's Health Initiative Observational Study, vaginal estrogen users were compared against non-users for breast cancer, endometrial cancer and cardiovascular events. That is observational and cannot establish causation, which is exactly why the question of who can use this after a breast cancer diagnosis is still decided case by case with an oncologist rather than settled by a label.
The boxed warning is coming off, unevenly, and we counted
The FDA announced removal of the boxed warnings from menopause hormone therapy in November 2025 and approved the labeling changes in February 2026. Manufacturers repost their labels on their own schedules, so the leaflet inside the box you are handed today depends on who made it and when they last updated.
We counted the SPL section code for a boxed warning across 4 vaginal estrogen labels on DailyMed on 2026-08-15. Method: LOINC 34066-1 (BOXED WARNING SECTION) counted in the DailyMed SPL XML. 1 of 4 came back clean: Estring (estradiol vaginal system), reposted 2026-04-23. The other 3 still carry one, and every one of them was last posted before the November 2025 announcement: Imvexxy (estradiol vaginal inserts) (2025-09-16), Vagifem (estradiol vaginal inserts) 10 mcg (2025-02-10), Estradiol vaginal cream, USP, 0.01% (2025-05-30).
The three positives are the control on the method: the count detects the section where it exists, so the single absence is a finding rather than a failed read. Four labels on four independent update cycles, so this changes without notice. What the FDA has approved and what is printed on your leaflet are two different questions right now, and the second one is the one you can see. What the FDA actually changed.
What vaginal estrogen costs, provider by provider
Each line is the provider's own published product string, kept verbatim including its verification label. 4 of the 13women's-wing platforms we track dispense a local vaginal estrogen.
- Estradiol vaginal cream ($119.97/3-mo) · Cream
Product type: Both
- Vaginal estrogen cream ($89/mo) · Cream
Product type: Compounded
- Estradiol vaginal cream, from $20 [Verified July 2026] · Cream
Product type: Brand
- Vaginal estradiol · Form not specified
Product type: Compounded
The cheapest published monthly figure is Wisp, from $20/mo, against a platform price of $99/mo. No other hormone product in our women's-wing data carries a lower published per-month figure. That is a comparison across the listings that publish a price at all, and several pills and patches on the roster publish none. Full table on our cheapest HRT page, scores and grades on the rankings.
All 3 products above that name a form name the same one, cream. No platform on our roster lists insert or tablet or ring as its own local estrogen product, which is worth knowing before you shop: the ring is the form you replace once every three months rather than applying twice a week, and it is a prescription to ask a clinician for rather than something you can order from a telehealth platform we track. One qualifier, because our own data carries it: Wisp names a suppository among the forms of a single line that bundles estrogen and progesterone together. A bundled string cannot have its route attributed to either drug on its own, so that listing is counted nowhere on this page and it is not a published local vaginal estrogen product. Alloy price this product per multi-month supply. Their figures are shown in that unit rather than converted to a monthly rate, because dividing a published supply price into a monthly one produces a number the provider does not publish. Gala Health list the product with no price attached, so what it costs is not knowable before intake.
FAQ
Vaginal estrogen, answered
What is vaginal estrogen?
Vaginal estrogen is estrogen delivered into the vagina as a cream, an insert or a ring, dosed low enough to act on the local tissue rather than to treat whole-body menopause symptoms. It is used for genitourinary syndrome of menopause: dryness, burning, pain with sex, urinary urgency and recurrent urinary tract infections, all of which follow the vaginal and urethral tissue thinning as estrogen falls. One thing to know about where the approvals stop, because we read the labels: none of the 4 FDA-approved labels we checked names a urinary indication. Each of them is approved for vulvar and vaginal atrophy or for the painful sex that comes with it, so treating the urinary half is a prescriber's decision beyond the printed indication rather than something the label promises. Vaginal estrogen and systemic HRT are not the same prescription: a systemic patch or pill is dosed to reach the whole body and treat hot flashes, and a vaginal product is dosed in micrograms to stay largely where it is put.
How much does vaginal estrogen cost?
Across the 13 women's-wing platforms we price-verify, 4 dispense a local vaginal estrogen and 2 publish a monthly price for it. The cheapest is Wisp, whose published figure is from $20/mo, which is also the lowest per-month figure published against any hormone product anywhere in our women's-wing data. Alloy price theirs per multi-month supply rather than per month, so those figures are shown in the provider's own unit rather than converted. Gala Health list the product with no price at all.
Is vaginal estrogen safer than systemic HRT?
The dose is far lower and the labels report the systemic exposure, which is the checkable part. On the Imvexxy (estradiol vaginal inserts) label, after 14 daily doses the mean serum estradiol concentration was 3.6 pg/mL on the 4 mcg insert, 4.6 pg/mL on the 10 mcg insert, and 4.3 pg/mL on placebo, so the placebo arm sat between the two active doses. On the Estring (estradiol vaginal system) label the mean systemically absorbed dose is put at about 8 percent of the amount released locally each day. That is the evidence for low systemic exposure. It is not the same claim as proven safety: every one of these products still carries the class contraindications, including known or suspected estrogen-dependent cancer, and a woman with a uterus using a systemic dose still needs endometrial cover. The Menopause Society addressed the question directly in its 2020 genitourinary syndrome of menopause position statement, which is the document to bring to the appointment.
Does vaginal estrogen require progesterone?
Progesterone is prescribed to oppose SYSTEMIC estrogen in a woman with a uterus. Low-dose vaginal estrogen is dosed to stay local, and the FDA-approved insert labels state the general rule in their dosage sections: "Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy." Those same labels carry a bleeding instruction, and it is narrower than the version usually repeated: "Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding." Whether your specific product and dose calls for a progestogen is a prescriber's call and not something to settle from a web page.
Does the genitourinary syndrome of menopause go away on its own?
Hot flashes usually fade over years. Genitourinary syndrome of menopause behaves differently: it is driven by the ongoing absence of estrogen in the vaginal and urinary tissue, so it tends to persist and to worsen slowly rather than resolve, and it comes back when treatment stops. That is why it is one of the few menopause indications where long-term local treatment is standard rather than exceptional. The 2014 terminology paper that introduced the name made the point explicitly: vulvovaginal atrophy was renamed because the old term described only part of a condition that also involves urinary symptoms and recurrent infections.
What is the difference between the cream, the insert and the ring?
Frequency and mess, mostly. On the generic estradiol vaginal cream label the regimen is 2 to 4 g on the marked applicator daily for one or two weeks, then gradually reduced to half that, and the label adds that a maintenance dose of 1 g one to three times a week may be used once the vaginal mucosa has been restored. Inserts are a fixed micro-dose: one daily for two weeks, then one twice weekly. The Estring (estradiol vaginal system) sits in the upper vagina and is replaced once every three months, releasing about 7.5 mcg of estradiol a day over 90 days. A cream lets a prescriber titrate the amount and is the messiest to use. An insert is a fixed strength, so the dose does not depend on how much you apply. A ring is the least frequent thing to remember, at once every three months. On our roster, every local vaginal estrogen listing that names a form names cream, and no platform we track lists insert or tablet or ring as its own local estrogen product, so those are prescriptions to ask a clinician for rather than something you can order from a telehealth platform we track.
Do vaginal estrogen products still carry the boxed warning?
It depends on which box you are handed, and we checked. Counting the SPL section code for a boxed warning across 4 vaginal estrogen labels on DailyMed on 2026-08-15: Estring (estradiol vaginal system), reposted 2026-04-23, carries none. Imvexxy (estradiol vaginal inserts) (2025-09-16), Vagifem (estradiol vaginal inserts) 10 mcg (2025-02-10), Estradiol vaginal cream, USP, 0.01% (2025-05-30) still carry one. The FDA announced removal of the boxed warnings from menopause hormone therapy in November 2025 and approved the labeling changes in February 2026, and manufacturers repost on their own schedule, so the warning printed on the leaflet inside your box depends on when your manufacturer last updated. Re-check before relying on this: these are four labels on four independent update cycles.
Related
- Estradiol, explained and then priced every systemic form, side by side
- Progesterone and why it is in your regimen the drug this route generally does not need
- Perimenopause where these symptoms usually start
- Cheapest verified HRT and the full rankings
Sources
- Estring (estradiol vaginal system) prescribing information, Pfizer, DailyMed (SPL effective 2026-04-23, read from the structured XML on 2026-08-15). Approval record, FDA Drugs@FDA
- Imvexxy (estradiol vaginal inserts) prescribing information, Mayne Pharma, DailyMed (SPL effective 2025-09-16, read from the structured XML on 2026-08-15). Approval record, FDA Drugs@FDA
- Vagifem (estradiol vaginal inserts) 10 mcg prescribing information, Novo Nordisk, DailyMed (SPL effective 2025-02-10, read from the structured XML on 2026-08-15). Approval record, FDA Drugs@FDA
- Estradiol vaginal cream, USP, 0.01% prescribing information, Prasco Laboratories, DailyMed (SPL effective 2025-05-30, read from the structured XML on 2026-08-15)
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society (PMID 32852449)
- Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy, ISSWSH and NAMS (PMID 25160739)
- Vaginal estrogen for genitourinary syndrome of menopause: a systematic review, Obstet Gynecol 2014 (PMID 25415166)
- Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study, Menopause 2018 (PMID 28816933)
- The 2022 hormone therapy position statement of The North American Menopause Society (PMID 35797481)
This is general information, not medical advice. Vaginal estrogen is a prescription medicine, and whether it is right for you, at which dose and in which form, is a decision for you and a licensed clinician. If you have a history of breast cancer, that conversation belongs with your oncologist. Reviewed by Iacob Pastina.
Midi Health
Sesame Care